Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
In this Review, we summarize current preclinical and clinical evidence, showing that the riskbenefit profile of GLP1RAs remains favourable in individuals with T2DM and obesity, although caution is warranted in those with a low cardiometabolic risk, for whom the potential risks of cancer might outweigh any expected benefits
Our understanding of Parkinsons disease (PD) has evolved from the initial focus on motor symptoms to now include non-motor symptoms of the disease (such as mood, fatigue, constipation)
The improved tissue healing from peptide therapy may actually enhance the effectiveness of physical interventions
"Food stimulates the release of GLP-1 from your intestinal cells, which then signals your pancreas to release insulin, improves satiety, and slows digestion." This natural process helps control appetite and blood sugar without medication
Are you taking a GLP-1 medication and wondering what you should actually eat to maximize your results